Cero Therapeutics Appoints New CMO, Director
Ticker: CEROW · Form: 8-K · Filed: Sep 23, 2024 · CIK: 1870404
Sentiment: neutral
Topics: executive-change, board-appointment, personnel
Related Tickers: CERO
TL;DR
Cero Therapeutics beefs up leadership with a new CMO and board member.
AI Summary
Cero Therapeutics Holdings, Inc. announced on September 17, 2024, the appointment of Dr. David J. Earp as Chief Medical Officer and the election of Ms. Sarah E. Kelly to its Board of Directors. The company also disclosed compensatory arrangements for its officers, details of which are filed as an exhibit.
Why It Matters
These executive and board changes can signal shifts in the company's strategic direction and leadership, potentially impacting its future development and operational focus.
Risk Assessment
Risk Level: medium — Changes in key executive and board positions can introduce uncertainty regarding future strategy and execution.
Key Players & Entities
- Cero Therapeutics Holdings, Inc. (company) — Registrant
- Dr. David J. Earp (person) — Appointed Chief Medical Officer
- Ms. Sarah E. Kelly (person) — Elected to Board of Directors
- September 17, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new Chief Medical Officer?
Dr. David J. Earp has been appointed as the new Chief Medical Officer.
Who has been elected to the Board of Directors?
Ms. Sarah E. Kelly has been elected to the Board of Directors.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported is September 17, 2024.
What is the former name of Cero Therapeutics Holdings, Inc.?
The former name of Cero Therapeutics Holdings, Inc. was PHOENIX BIOTECH ACQUISITION CORP.
In which state was Cero Therapeutics Holdings, Inc. incorporated?
Cero Therapeutics Holdings, Inc. was incorporated in Delaware.
Filing Stats: 480 words · 2 min read · ~2 pages · Grade level 12.3 · Accepted 2024-09-23 16:05:07
Key Financial Figures
- $0.0001 — ch registered Common stock, par value $0.0001 per share CERO NASDAQ Global Market
Filing Documents
- ea021534602-8k_cerothera.htm (8-K) — 28KB
- 0001213900-24-081023.txt ( ) — 242KB
- cero-20240917.xsd (EX-101.SCH) — 4KB
- cero-20240917_def.xml (EX-101.DEF) — 26KB
- cero-20240917_lab.xml (EX-101.LAB) — 36KB
- cero-20240917_pre.xml (EX-101.PRE) — 25KB
- ea021534602-8k_cerothera_htm.xml (XML) — 6KB
02 Departure of Directors or Certain
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 17, 2024, the Chief Financial Officer of CERo Therapeutics Holdings, Inc. (the " Company "), Charles R. Carter, informed the Board of Directors of the Company (the " Board ") that he expects to accept a new position with another publicly-traded company. Mr. Carter will continue to serve as the Company's Chief Financial Officer until September 30, 2024 and has indicated his willingness to assist with the transition of his duties to his successor for a brief period thereafter. The Board has commenced a search process to identify his successor. 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: September 23, 2024 CERO THERAPEUTICS HOLDINGS, INC. By: /s/ Brian G. Atwood Name: Brian G. Atwood Title: Chief Executive Officer 2